1-2 of 2
Chiara Lobetti-Bodoni
Close
Sort by
Journal Articles

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martínez-López, Yucai Wang, Brian K. Link
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5835–5843.
https://doi.org/10.1182/bloodadvances.2022008150
Published: 2022
Journal Articles

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4816–4820.
https://doi.org/10.1182/bloodadvances.2021006193
Published: 2022
Includes: Supplemental data